Skip to content

D615L vs Zeiss 839MP: Visual Quality

A Comparative Study on Postoperative Visual Quality: New Domestic Trifocal IOL (D615L) Versus Zeiss AT LISA Tri 839MP

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07571694
Enrollment
90
Registered
2026-05-06
Start date
2025-04-01
Completion date
2026-12-31
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Keywords

Cataract

Brief summary

The goal of this prospective cohort study is to compare visual quality after cataract surgery in patients implanted with a new domestic trifocal intraocular lens (D615L) versus the Zeiss AT LISA tri 839MP. The main question it aims to answer is: Is the uncorrected distance, intermediate, and near visual acuity achieved with D615L non-inferior or superior to that achieved with the Zeiss 839MP? Participants diagnosed with age-related cataract will undergo phacoemulsification and receive one of the two intraocular lenses. They will attend follow-up visits where uncorrected visual acuity, defocus curves, and the VF-14 questionnaire will be assessed over a follow-up period of at least 6 months.

Interventions

implanted D615L

Sponsors

Shanghai 10th People's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* diagnosed age-related cataract; * preoperative corneal astigmatism \<1.0 D; * endothelial cell count \>2000/mm²; * signed informed consent and ability to complete 6-month follow-up

Exclusion criteria

* prior corneal refractive, glaucoma or vitreoretinal surgery; * intraoperative posterior capsule rupture, zonular dehiscence or vitreous loss; * corneal pathology, macular edema or optic neuropathy affecting visual assessment; * active ocular inflammation, glaucoma, maculopathy or diabetic retinopathy; * uncontrolled systemic disease such as diabetes or autoimmune disorders.

Design outcomes

Primary

MeasureTime frameDescription
UIVAFrom enrollment to the end of treatment at 6 monthsuncorrected-intermediate visual acuity

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026